Placebo effects in adult and adolescent patients with schizophrenia

combined analysis of nine RCTs

Kenichiro Kubo, W. W. Fleischhacker, T. Suzuki, N. Yasui-Furukori, Masaru Mimura, Hiroyuki Uchida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To examine characteristics of placebo responders and seek optimal criteria of early improvement with placebo for predicting subsequent placebo response in patients with schizophrenia. Method: Data of 672 patients with schizophrenia randomized to placebo in nine double-blind antipsychotic trials were analyzed. Multiple logistic regression analyses were conducted to examine associations between placebo response at week 6 (i.e., a ≥ 25% reduction in the Positive and Negative Syndrome Scale [PANSS] score) and gender, age, study locations, baseline PANSS total or Marder 5-Factor scores, and per cent PANSS score reduction at week 1. Predictive power of improvement at week 1 for subsequent response was investigated; sensitivity and specificity of incremental 5% cutoff points between 5% and 25% reduction in the PANSS total score at week 1 were calculated. Results: Per cent PANSS total score reduction at week 1 and lower PANSS Marder disorganized thought scores at baseline were significantly associated with subsequent placebo response. A 10% reduction in a per-protocol analysis or a 15% reduction in last-observation-carried-forward analysis in the PANSS total score at week 1 showed the highest predictive power. Conclusion: These findings are informative to identify potential placebo responders at the earliest opportunity for optimal trial design for schizophrenia.

Original languageEnglish
JournalActa Psychiatrica Scandinavica
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Placebo Effect
Schizophrenia
Placebos
Antipsychotic Agents
Logistic Models
Regression Analysis
Observation
Sensitivity and Specificity

Keywords

  • antipsychotic agents
  • placebo effect
  • placebos
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Placebo effects in adult and adolescent patients with schizophrenia : combined analysis of nine RCTs. / Kubo, Kenichiro; Fleischhacker, W. W.; Suzuki, T.; Yasui-Furukori, N.; Mimura, Masaru; Uchida, Hiroyuki.

In: Acta Psychiatrica Scandinavica, 01.01.2018.

Research output: Contribution to journalArticle

@article{a91a3097ec4f42408a12c7a9ec74931c,
title = "Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs",
abstract = "Objective: To examine characteristics of placebo responders and seek optimal criteria of early improvement with placebo for predicting subsequent placebo response in patients with schizophrenia. Method: Data of 672 patients with schizophrenia randomized to placebo in nine double-blind antipsychotic trials were analyzed. Multiple logistic regression analyses were conducted to examine associations between placebo response at week 6 (i.e., a ≥ 25{\%} reduction in the Positive and Negative Syndrome Scale [PANSS] score) and gender, age, study locations, baseline PANSS total or Marder 5-Factor scores, and per cent PANSS score reduction at week 1. Predictive power of improvement at week 1 for subsequent response was investigated; sensitivity and specificity of incremental 5{\%} cutoff points between 5{\%} and 25{\%} reduction in the PANSS total score at week 1 were calculated. Results: Per cent PANSS total score reduction at week 1 and lower PANSS Marder disorganized thought scores at baseline were significantly associated with subsequent placebo response. A 10{\%} reduction in a per-protocol analysis or a 15{\%} reduction in last-observation-carried-forward analysis in the PANSS total score at week 1 showed the highest predictive power. Conclusion: These findings are informative to identify potential placebo responders at the earliest opportunity for optimal trial design for schizophrenia.",
keywords = "antipsychotic agents, placebo effect, placebos, schizophrenia",
author = "Kenichiro Kubo and Fleischhacker, {W. W.} and T. Suzuki and N. Yasui-Furukori and Masaru Mimura and Hiroyuki Uchida",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/acps.12960",
language = "English",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Placebo effects in adult and adolescent patients with schizophrenia

T2 - combined analysis of nine RCTs

AU - Kubo, Kenichiro

AU - Fleischhacker, W. W.

AU - Suzuki, T.

AU - Yasui-Furukori, N.

AU - Mimura, Masaru

AU - Uchida, Hiroyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To examine characteristics of placebo responders and seek optimal criteria of early improvement with placebo for predicting subsequent placebo response in patients with schizophrenia. Method: Data of 672 patients with schizophrenia randomized to placebo in nine double-blind antipsychotic trials were analyzed. Multiple logistic regression analyses were conducted to examine associations between placebo response at week 6 (i.e., a ≥ 25% reduction in the Positive and Negative Syndrome Scale [PANSS] score) and gender, age, study locations, baseline PANSS total or Marder 5-Factor scores, and per cent PANSS score reduction at week 1. Predictive power of improvement at week 1 for subsequent response was investigated; sensitivity and specificity of incremental 5% cutoff points between 5% and 25% reduction in the PANSS total score at week 1 were calculated. Results: Per cent PANSS total score reduction at week 1 and lower PANSS Marder disorganized thought scores at baseline were significantly associated with subsequent placebo response. A 10% reduction in a per-protocol analysis or a 15% reduction in last-observation-carried-forward analysis in the PANSS total score at week 1 showed the highest predictive power. Conclusion: These findings are informative to identify potential placebo responders at the earliest opportunity for optimal trial design for schizophrenia.

AB - Objective: To examine characteristics of placebo responders and seek optimal criteria of early improvement with placebo for predicting subsequent placebo response in patients with schizophrenia. Method: Data of 672 patients with schizophrenia randomized to placebo in nine double-blind antipsychotic trials were analyzed. Multiple logistic regression analyses were conducted to examine associations between placebo response at week 6 (i.e., a ≥ 25% reduction in the Positive and Negative Syndrome Scale [PANSS] score) and gender, age, study locations, baseline PANSS total or Marder 5-Factor scores, and per cent PANSS score reduction at week 1. Predictive power of improvement at week 1 for subsequent response was investigated; sensitivity and specificity of incremental 5% cutoff points between 5% and 25% reduction in the PANSS total score at week 1 were calculated. Results: Per cent PANSS total score reduction at week 1 and lower PANSS Marder disorganized thought scores at baseline were significantly associated with subsequent placebo response. A 10% reduction in a per-protocol analysis or a 15% reduction in last-observation-carried-forward analysis in the PANSS total score at week 1 showed the highest predictive power. Conclusion: These findings are informative to identify potential placebo responders at the earliest opportunity for optimal trial design for schizophrenia.

KW - antipsychotic agents

KW - placebo effect

KW - placebos

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85052911402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052911402&partnerID=8YFLogxK

U2 - 10.1111/acps.12960

DO - 10.1111/acps.12960

M3 - Article

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

ER -